PLSE
Pulse Biosciences, Inc.
Healthcare — Medical Instruments & Supplies
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment cycle; and nPulse Console, a software-enabled console-based platform designed to accommodate the clinical workflow preferred by physicians. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida.
Price History
Fundamentals
| Market Cap | $1.96B |
| P/E Ratio (TTM) | - |
| Forward P/E | -25.99 |
| EPS (TTM) | $-1.10 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -80.72% |
| Debt/Equity | 10.79 |
| Recommendation | None |
| Analyst Target | $30.67 |
| Analysts | 3 |
| Next Earnings | Aug 6, 2026 AMC |
| Indexes | - |
Technical Indicators
| RSI (14) | 62.2 |
| Beta | 1.66 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $31.00 |
| 52-Week Low | $12.56 |
| 50-Day Avg | $24.38 |
| 200-Day Avg | $19.11 |
| Avg Volume | 343.7K |
| Volume | 228.3K |
Performance Analysis
NEUTRALPLSE presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jul 02, 2026 13:26 UTC
Back to Screener Export Report